Document:

EX-4.16

 Exhibit 4.16 

  
 

 
  
 1 

 

 ROLLOVER OPTION PLAN 

NEWAMSTERDAM PHARMA COMPANY N.V. 

INTRODUCTION 
 Article 1 

This document sets out rules relating to the Rollover Options. 

DEFINITIONS AND INTERPRETATION 
 Article 2 

 

	2.1	 In this Plan the following definitions shall apply: 

 

					
	    	 	Article	 	An article of this Plan.
			
		 	BCA	 	The Business Combination Agreement dated July 25, 2022 and entered into among the Company, Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation and NewAmsterdam Pharma Holding B.V.
			
		 	Board	 	The Company’s board of directors.
			
		 	Change of Control	 	 The occurrence of any one or more of the following events (which, for the avoidance of doubt, do not include the Closing or any events
occurring prior to the Closing):
  

a.  the direct or indirect change in ownership or control of the Company effected through one
transaction, or a series of related transactions within a twelve-month period, as a result of which any Person or group of Persons acting in concert, directly or indirectly acquires (i) beneficial ownership of more than half of the
Company’s issued share capital and/or (ii) the ability to cast more than half of the voting rights in the General Meeting;
  

b.  at any time during a period of twelve consecutive months, individuals who at the beginning of
such period constituted the Board cease to constitute a majority of members of the Board, provided that any new Director who was nominated for appointment by the Board by a vote of at least a majority of the Directors who either were Directors at
the beginning of such twelve-month period or whose nomination for appointment was so approved, shall be considered as though such individual were a Director at the beginning of such twelve-month
period;

 

 
  
 
 2
 
  

					
	    	 		 	 c.   the consummation of a merger, demerger or business combination of the
Company or any Subsidiary with another Person, unless such transaction results in the shares in the Company’s capital outstanding immediately prior to the consummation of such transaction continuing to represent (either by remaining outstanding
or by being converted into, or exchanged for, voting securities of the surviving or acquiring Person or a parent thereof) at least half of the voting rights in the General Meeting or in the shareholders’ meeting of such surviving or acquiring
Person or parent outstanding immediately after the consummation of such transaction;
  

d.  the consummation of any sale, lease, exchange or other transfer to any Person or group of
Persons acting in concert, not being Subsidiaries, in one transaction or a series of related transactions within a twelve-month period, of all or substantially all of the business of the Company and its Subsidiaries; or

 
 e.   such other event
which the Committee reasonably determines to constitute a change of control in respect of the Company.

			
		 	Closing	 	The consummation of the transactions contemplated by the BCA.
			
		 	Closing Date	 	The date of the Closing.
			
		 	Committee	 	 The following body, as applicable:
  

a.  the Board, to the extent the administration or operation of this Plan relates to Rollover
Options held by Participants who are members of the compensation committee established by the Board; or

 

 
  
 
 3
 
  

					
	    	 		 	 b.  the compensation committee established by the Board for all other matters
relating to the administration or operation of the Plan.

			
		 	Company	 	NewAmsterdam Pharma Company N.V.
			
		 	DCC	 	The Dutch Civil Code.
			
		 	Director	 	A member of the Board.
			
		 	DR	 	A depository receipt for a Share issued by Stichting Administratiekantoor EPNAP.
			
		 	Exercise Date	 	The date on which a Rollover Option is duly exercised by or on behalf of the Participant concerned.
			
		 	Exercise Price	 	The exercise price applicable to a Rollover Option.
			
		 	FMV	 	The closing price of a Share on the relevant date (or, if there is no reported sale of Shares on such date, on the last preceding date on which any such reported sale occurred) on the principal stock exchange where Shares have been
admitted for trading, unless determined otherwise by the Committee.
			
		 	General Meeting	 	The Company’s general meeting of shareholders.
			
		 	Grant Date	 	The date on which the relevant Rollover Options were originally granted by NewAmsterdam Pharma Holding B.V. as specified in Annex A.
			
		 	Participant	 	The holder of a Rollover Option, including, as the context may require, the rightful heir(s) of a previous holder of such Rollover Option having acquired such Rollover Option as a result of the death of such previous
holder.
			
		 	Performance Criteria	 	The performance criteria applicable to a Rollover Option.
			
		 	Person	 	A natural person, partnership, company, association, cooperative, mutual insurance society, foundation or any other entity or body which operates externally as an independent unit or organisation.
			
		 	Plan	 	This Rollover Option plan.
			
		 	Plan Share	 	A Share underlying a Rollover Option.
			
		 	Rollover Options	 	The options to subscribe for or otherwise acquire Shares as listed in Annex A to this Plan, originally issued by NewAmsterdam Pharma Holding B.V. and assumed by the Company, all of which are “Rollover Company Options” as
defined by the BCA.

 

 
  
 
 4
 
  

					
	    	 	Rollover Option Agreements	 	The agreements governing the existence of the Rollover Options between the Company, NewAmsterdam Pharma Holding B.V. and the respective Participants, in each case dated on or about the Closing Date (as amended from time to
time).
			
		 	Share	 	An ordinary share in the Company’s capital.
			
		 	Subsidiary	 	A subsidiary of the Company within the meaning of Section 2:24a DCC.
			
		 	Transfer	 	The (i) sale or assignment of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or
increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Securities and Exchange Act of 1934, as amended, and the rules and regulations of the United
States Securities and Exchange Commission promulgated thereunder, with respect to, any security, (ii) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any
security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii) public announcement of any intention to effect any transaction specified in clause (i) or (ii).

  

	2.2	 References to statutory provisions are to those provisions as they are in force from time and as amended to
time. 

  

	2.3	 Terms that are defined in the singular have a corresponding meaning in the plural. 

 

	2.4	 Words denoting a gender include each other gender. 

 

	2.5	 Except as otherwise required by law, the terms “written” and “in writing” include the use
of electronic means of communication. 

 

 
  
 
 5
 
  

 ADMINISTRATION 

Article 3 
  

	3.1	 This Plan shall be administered by the Committee. The Committee’s powers and authorities under this Plan
include the authority to perform the following matters, in each case consistent with and subject to the terms of this Plan: 

  

	 	a.	 amending or waiving the terms applicable to outstanding Rollover Options (including Performance Criteria, if
applicable), provided that no such amendment shall take effect without the consent of the affected Participant(s), if such amendment would materially and adversely affect the rights of the Participant(s) under such Rollover Options, except to the
extent that any such amendment is made to cause this Plan or the Rollover Options concerned to comply with applicable law, stock exchange rules, accounting principles or tax rules and regulations; 

 

	 	b.	 making any determination under, and interpreting the terms of, this Plan, any rules or regulations issued
pursuant to this Plan and any Rollover Option Agreement; 

  

	 	c.	 correcting any defect, supplying any omission or reconciling any inconsistency in the Plan or any Rollover
Option Agreement; 

  

	 	d.	 settling any dispute between the Company and any Participant (including any beneficiary of his Rollover
Options) regarding the administration and operation of this Plan, any rules or regulations issued pursuant to this Plan, and any Rollover Option Agreement entered into with such Participant; and 

 

	 	e.	 making any other determination or taking any other action which the Committee considers to be necessary, useful
or desirable in connection with the administration or operation of this Plan. 

  

	3.2	 The Committee may issue further rules and regulations for the administration and operation of this Plan,
consistent with and subject to the terms of this Plan. 

  

	3.3	 All decisions of the Committee shall be final, conclusive and binding upon the Company and the Participants
(including beneficiaries of Rollover Options). 

 ROLLOVER OPTIONS 

Article 4 
  

	4.1	 The Rollover Options shall be governed by the terms and conditions, including vesting terms and applicable
Performance Criteria (if any), that applied to such Rollover Options immediately before being assumed by the Company, provided that, in case of any inconsistency between those terms and conditions and this Plan, the provisions of this Plan shall
prevail. 

  

	4.2	 No Rollover Option is intended to confer any rights on the relevant Participant except as set forth in the
applicable Rollover Option Agreement. In particular, no Rollover Option should be construed as giving any Participant the right to remain employed by or to continue to provide services for the Company or any Subsidiary. 

 

	4.3	 The exercise period for the Rollover Options shall expire on the tenth anniversary of their respective Grant
Dates, or on such earlier date as specified in the applicable Rollover Option Agreement. Unless determined otherwise by the Committee, if the exercise of a Rollover Option is prohibited by applicable law or the Company’s insider trading policy
on the last business day of such exercise period, such exercise period shall be extended for a period of one month following the end of such prohibition. 

 

 
  
 
 6
 
  

	4.4	 Unless determined otherwise by the Committee, Rollover Options cannot be transferred, pledged or otherwise
encumbered, except by testament or hereditary law as a result of death of the Participant concerned. 

  

	4.5	 If, as a result of changes in applicable law, accounting principles or tax rules and regulations, or due to a
variation of the composition of the Company’s issued share capital (including a share split, reverse share split, redenomination of the nominal value, or as a result of a dividend or other distribution, reorganisation, acquisition, merger,
demerger, business combination or other transaction involving the Company or a Subsidiary), an adjustment to this Plan, any Rollover Option Agreement and/or outstanding Rollover Options is necessary to prevent dilution or enlargement of the benefits
or potential benefits intended to be made available under this Plan, the Committee may adjust equitably any or all of: 

  

	 	a.	 the number of Plan Shares available under this Plan; 

 

	 	b.	 the number of Plan Shares underlying outstanding Rollover Options; and/or 

 

	 	c.	 the Exercise Price or other terms applicable to outstanding Rollover Options. 

 

	4.6	 Any rights, payments and benefits under any Rollover Option shall be subject to repayment and/or recoupment by
the Company in accordance with applicable law, stock exchange rules and such policies and procedures as the Company may adopt from time to time. 

VESTING AND EXERCISE 
 Article 5 

 

	5.1	 Upon the exercise of vested Rollover Options, the Company shall be obliged to deliver to the Participant
concerned (or the beneficiary of such Rollover Options, as applicable), the Plan Shares underlying such Rollover Options or, if such Participant elects to receive DRs instead of Plan Shares, the equivalent number of DRs. 

 

	5.2	 Only vested Rollover Options may be exercised in accordance with their terms. A Rollover Option can only be
exercised by or on behalf of the Participant holding such Rollover Option. Notwithstanding anything to the contrary in this Plan, the exercise of a vested Rollover Option shall always be and remain suspended until a registration statement
registering the issuance of the Plan Shares issuable pursuant thereto has been filed with the United States Securities and Exchange Commission. 

  

	5.3	 A Rollover Option can only be exercised through the use of an electronic system or platform to be designated by
the Committee (if and when such system or platform has been set up by the Company), or otherwise by delivering written notice to the Company in a form approved by the Committee. 

 

 
  
 
 7
 
  

	5.4	 Upon the exercise of a Rollover Option, the applicable Exercise Price must immediately be paid in cash, wire
transfer of immediately available funds or by check payable to the order of the Company, provided that the Committee, subject to applicable law, may allow such Exercise Price to be satisfied on a cashless or net settlement basis, applying any of the
following methods (or a combination thereof): 

  

	 	a.	 by means of an immediate sale by or on behalf of the relevant Participant of part of the Plan Shares underlying
the Rollover Option(s) being exercised, with sale proceeds equal to the Exercise Price being remitted to the Company and any remaining net sale proceeds (less applicable costs, if any) being paid to such Participant; 

 

	 	b.	 by means of the relevant Participant forfeiting his entitlement to receive part of the Plan Shares underlying
the Rollover Option(s) being exercised at FMV on the Exercise Date and charging the aggregate nominal value of the remaining Plan Shares underlying such Rollover Option(s) against the Company’s reserves which are recognized for Dutch dividend
withholding tax purposes; 

  

	 	c.	 by means of the relevant Participant surrendering his entitlement to receive part of the Plan Shares underlying
the Rollover Option(s) being exercised at FMV on the Exercise Date, against the Company becoming due an equivalent amount to such Participant and setting off that obligation against the Company’s receivable with respect to payment of the
applicable Exercise Price; or 

  

	 	d.	 by means of the relevant Participant surrendering and transferring Shares to the Company (which may include
Plan Shares underlying the Rollover Option(s) being exercised) at FMV on the Exercise Date. 

  

	5.5	 When a Rollover Option is exercised, the Company shall, at the discretion of the Committee, subject to
applicable law and the Company’s insider trading policy: 

  

	 	a.	 issue new Plan Shares to the relevant Participant; or 

 

	 	b.	 transfer existing Plan Shares held by the Company to the relevant Participant, 

provided, in each case, that (i) Plan Shares may be delivered in the form of book-entry securities representing those Plan Shares (or
beneficial ownership of those Plan Shares entitling the holder to exercise or direct the exercise of voting rights attached thereto) credited to the securities account designated by the relevant Participant and (ii) if such Participant elects
to receive DRs instead of Plan Shares, the Company shall cause such DRs to be issued to the Participant. Furthermore, Plan Shares (or DRs, as applicable) may be delivered as described in the previous sentence to a Person designated by the relevant
Participant, with the prior approval of the Committee, as beneficiary of his Rollover Options. The Plan Shares (or DRs, as applicable) shall be delivered in such form(s) as may be determined by the Committee and shall be subject to such stop
transfer orders and other restrictions as the Committee may deem required or advisable. Furthermore, the Committee may determine that certificates for such Shares (or DRs, as applicable) shall bear an appropriate legend referring to the terms,
conditions and restrictions applicable thereto. 

 

 
  
 
 8
 
  

	5.6	 If a Rollover Option is exercised and such Rollover Option does not relate to a whole number of Plan Shares,
the number of Plan Shares underlying such Rollover Option shall be rounded down to the nearest integer. 

 PLAN SHARES AVAILABLE FOR
ROLLOVER OPTIONS Article 6 
  

	6.1	 Subject to Article 4.5, the Plan Shares underlying Rollover Options, irrespective of whether such Rollover
Options have been exercised, may not represent more than 1,736,545 Shares. 

  

	6.2	 Plan Shares underlying Rollover Options which expire, which are cancelled or otherwise terminated, shall no
longer be available under this Plan. 

 CHANGE OF CONTROL 

Article 7 
  

	7.1	 If long-term incentive awards are granted in assumption of, or in substitution or exchange for, outstanding
Rollover Options in connection with a Change of Control and the Committee has determined that such awards are sufficiently equivalent to the outstanding Rollover Options concerned, then such outstanding Rollover Options shall be cancelled and
terminated upon the replacement awards being granted to the Participants concerned. 

  

	7.2	 If, in connection with a Change of Control, outstanding Rollover Options are not replaced by long-term
incentive awards as described in Article 7.1, or are replaced by long-term incentive awards which the Committee does not consider to be sufficiently equivalent to such outstanding Rollover Options, then such Rollover Options shall immediately vest
in full, unless the Committee decides otherwise. 

  

	7.3	 For purposes of this Article 7, awards shall not be considered to be “sufficiently equivalent” to
outstanding Rollover Options, if the underlying securities are not widely held and publicly traded on a regulated national stock exchange. 

LOCK-UP 

Article 8 
  

	8.1	 In connection with any registration of the Company’s securities under United States securities laws, to
the extent requested by the Company or the underwriters managing any offering of the Company’s securities, and except as otherwise approved by the Committee or pursuant to any exceptions approved by such underwriters, a Participant may not
Transfer any Shares acquired by a Participant pursuant to the issuance, vesting or exercise of any Rollover Option prior to such period following the effective date of such registration as designated by such underwriters, not to exceed 180 days
following such registration. 

 

 
  
 
 9
 
  

	8.2	 The Company may impose stop-transfer instructions with respect to the Shares subject to the restriction
stipulated by Article 8.1 until the end of the lock-up period referred to in that provision. 

TAX 
 Article 9 

 

	9.1	 Any and all tax liability (e.g., any wage tax or income tax) and employee social security premiums due in
connection with or resulting from the granting, vesting, exercise of a Rollover Options (or the implementation of the Plan) or any payment or transfer under a Rollover Option (or under the Plan generally) shall be for the account of the relevant
Participant. 

  

	9.2	 The Company or any Subsidiary may, and each Participant shall permit the Company or any Subsidiary to, withhold
from any Rollover Options granted or any payment due or transfer made under any Rollover Options (or under the Plan generally) or from any compensation or other amount owing to a Participant the amount (in cash, Shares, other Rollover Options, other
property, net settlement or any combination thereof) of applicable income taxes or (wage) withholding taxes due in respect of a Rollover Option, the grant of a Rollover Option, its exercise (or the implementation of the Plan), or any payment or
transfer under such Rollover Option (or under the Plan generally) and to take such other action, including providing for (elective) payment of such amounts in cash or Shares by the Participant, as may be necessary in the option of the Company to
satisfy all obligations for the payment of such taxes. In addition, the Company may cause the sale by or on behalf of the relevant Participant of part of the Plan Shares underlying any Rollover Option being exercised, with sale proceeds equal to the
applicable wage or withholding taxes being remitted to the Company and any remaining net sale proceeds (less applicable costs, if any) being paid to such Participant. 

 

	9.3	 This Plan is governed by the tax laws and social security legislation and regulations prevailing at the date a
certain taxable event occurs. If any tax and/or employee social security legislation or regulations are amended and any tax or employee social security levies become payable as a result of such legislative amendment, the costs and the risk related
thereto shall be born solely by the relevant Participant. 

  

	9.4	 Notwithstanding the provisions of Article 9.2, where, in relation to a Rollover Option granted under this Plan,
the Company or any Subsidiary (as the case may be) is liable, or is in accordance with the current practice believed by the Committee to be liable, to account for any tax or social security authority for any sum in respect of any tax or social
security liability of the Participant, the Rollover Option may not be exercised unless the relevant Participant has paid to the Company or the relevant Subsidiary (as the case may be) an amount sufficient to discharge the liability).

 

 
  
 
 10
 
  

	9.5	 If, and to the extent, the Company or any Subsidiary (as the case may be) is not reimbursed, by means of the
provisions of Article 9.2 or 9.4, for any wage tax or income tax, employee’s social security contributions liability or any other liabilities for which the Company or a Subsidiary (as the case may be) has an obligation to withhold and account,
the Participant shall indemnify and hold harmless the Company or any Subsidiary (as the case may be) for any such taxes paid by the Company or any Subsidiary (as the case may be). 

 

	9.6	 For the avoidance of doubt, the provisions of this Article 9 shall apply to a Participant’s liabilities
that may arise on a taxable event in any jurisdiction. 

 DATA PROTECTION 

Article 10 
  

	10.1	 The Company may process personal data relating to the Participants in connection with the administration and
operation of this Plan. The personal data of the Participants which may be processed in this respect may include a copy of an identification document, contact details and bank and securities account numbers. Each Participant’s personal data
shall be stored by the Company for such time period as is necessary to administer such Participant’s participation in the Plan or as otherwise permitted under applicable law. 

 

	10.2	 Each Participant’s personal data shall be handled by the Company in accordance with applicable law,
including the General Data Protection Regulation (GDPR) and the rules and regulations promulgated pursuant thereto. Participants have the right to lodge complaints with an applicable supervisory authority regarding the Company’s processing of
personal data pursuant to this Plan. 

  

	10.3	 The Company shall implement technical, physical and organisational measures designed to protect personal data
processed pursuant to Article 10.1. Personnel or third parties that have access to such personal data shall be bound by confidentiality obligations. 

  

	10.4	 The Company shall abide by any statutory rights the Participants may have regarding their respective personal
data processed pursuant to Article 10.1, which may include the right to access, rectification, erasure, restriction of processing, objection to processing and portability of such personal data. 

 

	10.5	 In connection with the administration and operation of this Plan, the Company may transfer personal data
processed pursuant to Article 10.1 to one or more third parties, provided that there is a legitimate interest in doing so. Where such third parties are located outside the European Economic Area in countries that are not considered to provide for an
adequate level of data protection, the Company shall ensure that sufficient data protection safeguards are put in place, failing which explicit consent for such transfer shall be obtained from the Participant(s) concerned. 

 

	10.6	 The Company may establish one or more privacy policies providing further information on data protection and
applying to the processing of personal data of the Participants by the Company in connection with the administration and operation of this Plan. 

 

 
  
 
 11
 
  

 AMENDMENTS, TERM AND TERMINATION Article 11 

 

	11.1	 Except to the extent prohibited by applicable law and unless otherwise expressly provided in an Rollover Option
Agreement, the Board may amend, supplement, suspend or terminate this Plan (or any portion thereof) pursuant to a resolution to that effect, provided that no such amendment, supplement, suspension or termination shall take effect without:

  

	 	a.	 approval of the General Meeting, if such approval is required by applicable law or stock exchange rules; and/or

  

	 	b.	 the consent of the affected Participant(s), if such action would materially and adversely affect the rights of
such Participant(s) under any outstanding Rollover Option, except to the extent that any such amendment, supplement or termination is made to cause this Plan to comply with applicable law, stock exchange rules, accounting principles or tax rules and
regulations. 

  

	11.2	 Notwithstanding anything to the contrary in the Plan, the Committee may amend the Plan and/or any Rollover
Option Agreement in such manner as may be necessary or desirable to enable the Plan and/or such Rollover Option Agreement to achieve its stated purposes in any jurisdiction in a tax-efficient manner and in
compliance with local laws, rules and regulations to recognise differences in local law, tax policy or custom. The Committee also may impose conditions on the exercise or vesting of Rollover Option in order to minimise the Company’s obligation
with respect to tax equalisation for Participants on assignments outside their home country and/or to enable the Company to meet its obligations with respect to the withholding of taxes and social security contributions. 

 

	11.3	 The Plan shall become effective on the Closing Date and immediately prior to the Merger (as defined in
the BCA). 

 GOVERNING LAW AND JURISDICTION 

Article 12 
 This Plan shall be governed by and shall be
construed in accordance with the laws of the Netherlands. Subject to Article 3.1 paragraph d., any dispute arising in connection with these rules shall be submitted to the exclusive jurisdiction of the competent court in Amsterdam, the Netherlands.EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 

AMENDMENT NO. 18 

AMENDMENT NO. 18 TO THE CREDIT AGREEMENT, dated as of November 28, 2022 (this “Amendment”), among THE
SHERWIN-WILLIAMS COMPANY, an Ohio corporation (the “Company”), the Lenders party hereto, CITICORP USA, INC. (“CUSA”), as Administrative Agent (in such capacity, the “Administrative
Agent”), and CUSA, as Issuing Bank (in such capacity, the “Issuing Bank”). Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement referred to below.

 PRELIMINARY STATEMENTS: 

(1) The Company, the Administrative Agent, the Lenders from time to time party thereto and the Issuing Bank are parties to that certain Credit
Agreement, dated as of May 9, 2016 (as amended by Amendment No. 1 to the Credit Agreement, dated as of May 12, 2016, Amendment No. 2 to the Credit Agreement, dated as of June 20, 2016, Amendment No. 3 to the Credit
Agreement, dated as of August 1, 2016, Amendment No. 4 to the Credit Agreement, dated as of January 31, 2017, Amendment No. 5 to the Credit Agreement, dated as of February 13, 2017, Amendment No. 6 to the Credit
Agreement, dated as of February 27, 2017, Amendment No. 7 to the Credit Agreement, dated as of May 8, 2017, Amendment No. 8 to the Credit Agreement, dated as of May 11, 2017, Amendment No. 9 to the Credit Agreement,
dated as of February 27, 2018, Amendment No. 10 to the Credit Agreement, dated as of July 26, 2018, Amendment No. 11 to the Credit Agreement, dated as of September 14, 2020, Amendment No. 12 to the Credit Agreement,
dated as of November 9, 2020, Amendment No. 13 to the Credit Agreement, dated as of December 7, 2020, Amendment No. 14 to the Credit Agreement, dated as of February 16, 2021, Amendment No. 15 to the Credit Agreement,
dated as of May 3, 2021, Amendment No. 16 to the Credit Agreement, dated as of May 23, 2022, and Amendment No. 17 to the Credit Agreement, dated as of October 31, 2022, the “Existing Credit
Agreement”; the Existing Credit Agreement as amended by this Amendment, the “Credit Agreement”). 
 (2)
The Company has requested, and the Administrative Agent and the Lenders have agreed, on the terms and conditions set forth herein, to amend the Existing Credit Agreement as specified herein. 

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto hereby agree as follows: 
 SECTION 1. Amendments to the Existing Credit Agreement. Upon, and
subject to, the satisfaction or waiver in accordance with Section 9.02 of the Existing Credit Agreement of the conditions precedent set forth in Section 2 below, the Existing Credit Agreement is hereby amended as follows: 

(a) The following new definition is included in Section 1.01 of the Existing Credit Agreement in the proper alphabetical order as follows:

 ““Amendment No. 18 Effective Date” means November 28,
2022.” 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	1	  	Amendment No. 18 to Credit Agreement

 (b) Each of the following definitions in Section 1.01 of the Existing Credit Agreement
is hereby amended and restated in its entirety as follows: 
 ““Commitment” means, with respect
to each Lender, the commitment of such Lender to acquire participations in the Letter of Credit and to make Loans, as such commitment may be (a) reduced from time to time pursuant to Section 2.07, (b) reduced or increased from time to time
pursuant to assignments by or to such Lender pursuant to Section 9.04 or (c) reduced or increased from time to time pursuant to an amendment hereto. The amount of each Lender’s Commitment on the Amendment No. 18 Effective Date is
set forth on Schedule 2.01, or in the Assignment and Acceptance pursuant to which such Lender shall have assumed its Commitment, as applicable.” 

““Maturity Date” means (i) with respect to the Commitments in the aggregate principal amount
of $125,000,000, the Maturity Date shall mean June 20, 2023, (ii) with respect to the Commitments in the aggregate principal amount of $75,000,000, the Maturity Date shall mean June 20, 2025, (iii) with respect to the Commitments in the
aggregate principal amount of $200,000,000, the Maturity Date shall mean December 20, 2025, (iv) with respect to the Commitments in the aggregate principal amount of $75,000,000, the Maturity Date shall mean June 20, 2026, (v) with respect
to the Commitments in the aggregate principal amount of $150,000,000, the Maturity Date shall mean June 20, 2027, and (vi) with respect to the Commitments in the aggregate principal amount of $250,000,000, the Maturity Date shall mean
December 20, 2027.” 
 (c) Schedule 2.01 of the Existing Credit Agreement is hereby amended and restated in its entirety as set
forth in Schedule 2.01 attached hereto. 
 SECTION 2. Conditions of Effectiveness. This Amendment shall become effective on the date
(the “Amendment No. 18 Effective Date”) on which: 
 (a) the Administrative Agent
shall have received a counterpart signature page of this Amendment duly executed by (i) the Company, (ii) the Administrative Agent, (iii) the Lenders, and (iv) the Issuing Bank or, as to any of the foregoing parties, written
evidence reasonably satisfactory to the Administrative Agent that such party has executed this Amendment; 
 (b) the Administrative Agent
shall have received one or more counterparts of the Fee Letter Amendment No. 18, dated as of the date hereof, duly executed by the Company and Citicorp USA, Inc.; and 

(c) the representations and warranties set forth in Section 4 of this Amendment shall be true and correct in all respects. 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	2	  	Amendment No. 18 to Credit Agreement

 SECTION 3. Effect of this Amendment, Etc. 

(a) Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or
otherwise affect the rights and remedies of the Issuing Bank, the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions,
obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 

(b) Nothing herein shall be deemed to entitle the Company to a consent to, or a waiver, amendment, modification or other change of, any of the
terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances. 

(c) After the Amendment No. 18 Effective Date, each reference in any Loan Document to the Credit Agreement, to “this Agreement”,
“hereunder”, “hereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Existing Credit Agreement, as modified hereby. This Amendment shall constitute a “Loan Document” for
all purposes of the Credit Agreement and the other Loan Documents. 
 SECTION 4. Representations and Warranties. The Company
represents and warrants to the Administrative Agent and the Lenders that, on and as of the date hereof and on and as of the Amendment No. 18 Effective Date: 

(a) (i) The execution, delivery and performance by the Company of this Amendment and the transactions contemplated hereby have been duly
authorized by all necessary corporate action, and (ii) this Amendment has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms, except as may be limited by applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws of general applicability relating to or affecting creditors’ rights generally and subject to general
principals of equity, regardless of whether considered in a proceeding in equity or at law. 
 (b) The representations and warranties of the
Company contained in the Credit Agreement and any other Loan Document are true and correct in all material respects, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and
warranties are true and correct in all material respects as of such earlier date). 
 (c) Both before and after giving effect to this
Amendment, no Default or Event of Default has occurred and is continuing. 
 SECTION 5. Execution in Counterparts. This Amendment may
be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
Delivery by telecopier or other form of electronic communication of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment, it being understood and agreed
that the words “execution,” “signed,” “signature,” and words of similar import in, or with respect to, any Loan Document shall be deemed to include electronic signatures or the

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	3	  	Amendment No. 18 to Credit Agreement

 
keeping of records in electronic form (including, without limitation, the execution by means of “DocuSign”, or other similar platform or service approved by the Administrative Agent),
each of which shall be of the same effect, validity and enforceability as manually executed signatures or a paper-based recordkeeping system, as the case may be, to the extent and as provided for under applicable law, including the Electronic
Signatures in Global and National Commerce Act of 2000 (15 USC § 7001 et seq.), the Electronic Signatures and Records Act of 1999 (NY State Technology Law §§ 301-309), or any other similar state
laws based on the Uniform Electronic Transactions Act; provided, that any electronic signature delivered by means of “DocuSign”, or other similar third-party platform by one party shall be promptly followed by an email attestation
by such party to the recipient party confirming that such electronic signature so delivered is the signature of such party; provided, further, that upon the request of the Administrative Agent, any electronic signature shall be
followed by a manually executed counterpart as promptly as reasonably practicable. 
 SECTION 6. Governing Law. This Amendment shall
be governed by, and construed in accordance with, the laws of the State of New York. 
 SECTION 7. WAIVER OF JURY TRIAL. EACH PARTY
HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AMENDMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY
(WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

SECTION 8. Jurisdiction; Consent to Service of Process. 

(a) The Company hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the Supreme
Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating
to this Amendment, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such
New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by law. Nothing in this Amendment shall affect any right that the Administrative Agent or any Lender or the Issuing Bank may otherwise have to bring any action or proceeding relating to this Amendment against
the Company or its properties in the courts of any jurisdiction. 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	4	  	Amendment No. 18 to Credit Agreement

 (b) The Company hereby irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Amendment in any court referred to in subsection (b) of this Section.
Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	5	  	Amendment No. 18 to Credit Agreement

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by
their respective officers thereunto duly authorized, as of the date first above written. 
  

			
	THE SHERWIN-WILLIAMS COMPANY
		
	By:	 	 /s/ Jeffrey J. Miklich

		 	Name: Jeffrey J. Miklich
		 	Title:   Vice President and Treasurer

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  		  	Amendment No. 18 to Credit Agreement

 
			
	CITICORP USA, INC.,
	as Administrative Agent and as Issuing Bank
		
	By:	 	 /s/ David Jaffe

		 	Name: David Jaffe
		 	Title:   Vice President

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  		  	Amendment No. 18 to Credit Agreement

 
			
	CITIBANK, N.A.,
	as Lender
		
	By:	 	 /s/ John Chun

		 	Name: John Chun
		 	Title:   Vice President

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  		  	Amendment No. 18 to Credit Agreement

 Schedule 2.01 

Commitments 
  

	 	A.	 For the period ending on June 20, 2023: 

 

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	875,000,000	 
		  	  
	  
	 
	 Total
	  	$	875,000,000	 
		  	  
	  
	 

  

	 	B.	 For the period from and including June 21, 2023 to and including June 20, 2025:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	750,000,000	 
		  	  
	  
	 
	 Total
	  	$	750,000,000	 
		  	  
	  
	 

  

	 	C.	 For the period from and including June 21, 2025 to and including December 20, 2025:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	675,000,000	 
		  	  
	  
	 
	 Total
	  	$	675,000,000	 
		  	  
	  
	 

  

	 	D.	 For the period from and including December 21, 2025 to and including June 20, 2026:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	475,000,000	 
		  	  
	  
	 
	 Total
	  	$	475,000,000	 
		  	  
	  
	 

  

	 	E.	 For the period from and including June 21, 2026 to and including June 20, 2027:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	400,000,000	 
		  	  
	  
	 
	 Total
	  	$	400,000,000	 
		  	  
	  
	 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	Schedule 2.01 – 1	  	Amendment No. 18 to Credit Agreement

	 	F.	 For the period from and including June 21, 2027 to and including December 20, 2027:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	250,000,000	 
		  	  
	  
	 
	 Total
	  	$	250,000,000	 
		  	  
	  
	 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	Schedule 2.01 – 2	  	Amendment No. 18 to Credit Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]